Teleflex (NYSE:TFX) vs. Vasamed (OTCMKTS:VSMD) Financial Comparison

Teleflex (NYSE:TFX) and Vasamed (OTCMKTS:VSMD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Teleflex and Vasamed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99 billion	2.99	-$905.64 million	($23.29)	-6.04
Vasamed	N/A	N/A	N/A	N/A	N/A

Vasamed has lower revenue, but higher earnings than Teleflex.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Teleflex and Vasamed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1	6	4	1	2.42
Vasamed	0	0	0	0	0.00

Teleflex presently has a consensus target price of $152.90, suggesting a potential upside of 8.76%. Given Teleflex’s stronger consensus rating and higher possible upside, equities analysts plainly believe Teleflex is more favorable than Vasamed.

Profitability

This table compares Teleflex and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Vasamed	N/A	N/A	N/A

Insider & Institutional Ownership

95.6% of Teleflex shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 8.0% of Vasamed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Teleflex beats Vasamed on 8 of the 10 factors compared between the two stocks.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.